The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B

Haemophilia

Volumn 23, Issue 6, 2017, Pages 868-876

  Fernandez Bello I ^a   Stenmo, C ^b   Butta, N ^a   Lind, V ^b   Ezban, M ^b   Jimenez Yuste V ^a,c  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

pharmacodynamics; pharmacokinetics; rFVIIa; therapeutic drug monitoring; thrombin generation assay; thromboelastography

Indexed keywords

BLOOD CLOTTING FACTOR 7A; KAOLIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBOPLASTIN; TRYPSIN INHIBITOR; RECOMBINANT PROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASSAY; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; ENZYME SYNTHESIS; HEMATOMA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IN VIVO STUDY; MALE; MIDDLE AGED; MULTIPLE DRUG DOSE; OPEN STUDY; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN FUNCTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBIN GENERATION ASSAY; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; THROMBOELASTOGRAPHY; VOLUME OF DISTRIBUTION AT STEADY-STATE; YOUNG ADULT; BLOOD; METABOLIC CLEARANCE RATE; METABOLISM; TREATMENT OUTCOME;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIIA; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; THROMBIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85034210795     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13312     Document Type: Article

References (33)

1. Novo Nordisk. NovoSeven® summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000074/WC500030873.pdf. Accessed July 18, 2017.
2. ® summary of product characteristics. Food and Drug Administration. http://www.fda.gov/downloads/&/ucm056915.pdf. Accessed January 10, 2017.
3. Kavakli K, Makris M, Zulfikar B, et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost. 2006;95:600-605.
4. −1-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia. 2008;14:287-294.
5. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost. 1998;80:912-918.
6. Parameswaran R, Shapiro AD, Gill JC, et al. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia. 2005;11:100-106.
7. Young G, Cooper DL, Gut RZ. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008). Haemophilia. 2012;18:990-996.
8. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood. 2010;116:5734-5737.
9. Qi X, Zhao Y, Li K, et al. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors. Blood Coagul Fibrinolysis. 2014;25:754-760.
10. Young G, Sorensen B, Dargaud Y, et al. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood. 2013;121:1944-1950.
11. Chitlur M, Rivard GE, Lillicrap D, et al. Recommendations for performing thromboelastography/thromboelastometry in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:103-106.
12. −1 dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h. Haemophilia. 2011;17:e949-e957.
13. Viuff D, Andersen S, Sorensen BB, et al. Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients. Thromb Res. 2010;126:144-149.
14. Kenet G, Stenmo CB, Blemings A, et al. Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial. Thromb Haemost. 2010;103:351-359.
15. Sorensen B, Ingerslev J. Thromboelastography and recombinant factor VIIa-hemophilia and beyond. Semin Hematol. 2004;41:140-144.
16. Vila V, Aznar JA, Moret A, et al. Assessment of the thrombin generation assay in haemophilia: comparative study between fresh and frozen platelet-rich plasma. Haemophilia. 2013;19:318-321.
17. Salooja N, Perry DJ. Thrombelastography. Blood Coagul Fibrinolysis. 2001;12:327-337.
18. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4-15.
19. Hemker HC, Kremers R. Data management in thrombin generation. Thromb Res. 2013;131:3-11.
20. Morfini M, Jimenez-Yuste V, Eichler H, et al. Pharmacokinetic properties of two different recombinant activated factor VII formulations. Haemophilia. 2012;18:431-436.
21. Tiede A, Friedrich U, Stenmo C, et al. Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa). J Thromb Haemost. 2011;9:1191-1199.
22. Bysted BV, Scharling B, Moller T, et al. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Haemophilia. 2007;13:527-532.
23. Agerso H, Brophy DF, Pelzer H, et al. Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients. J Thromb Haemost. 2011;9:333-338.
24. −1) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres. Haemophilia. 2009;15:760-765.
25. Salaj P, Brabec P, Penka M, et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia. 2009;15:752-759.
26. Salaj P, Kubes R, Cetkovsky P, et al. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry. Thromb Res. 2014;133:162-167.
27. Santagostino E, Mancuso ME, Rocino A, et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost. 2006;4:367-371.
28. Young G, Blain R, Nakagawa P, et al. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia. 2006;12:598-604.
29. Salinas V, Carmona R, Mohammed BM, et al. Is some better than none: are TEG and TGA profiles different in severe FVIII-deficient patients with inhibitors? Haemophilia. 2015;21:398-404.
30. Ay Y, Balkan C, Karapinar DY, et al. Feasibility of using thrombin generation assay (TGA) for monitoring of haemostasis during supplementation therapy in haemophilic patients without inhibitors. Haemophilia. 2012;18:911-916.
31. Ingerslev J, Poulsen LH, Sorensen B. Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. Haemophilia. 2003;9:348-352.
32. Brummel KE, Paradis SG, Butenas S, et al. Thrombin functions during tissue factor-induced blood coagulation. Blood. 2002;100:148-152.
33. Rivard GE, Brummel-Ziedins KE, Mann KG, et al. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost. 2005;3:2039-2043.